Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec reports 7% rise in revenues

Biogen Idec reports 7% rise in revenues

11th February 2010

Biogen Idec has unveiled its financial results for 2009, revealing a revenue rise of seven per cent for the full year.

During the 12-month period, the firm’s revenues increased to $4.4 billion (2.8 billion pounds), a rise the company attributes to the continued growth of its treatment TYSABRI (natalizumab).

Sales of the therapy grew by 32 per cent to $776 million, while AVONEX (interferon beta-1a) revenues rose by five per cent to a total of $2.3 billion.

Meanwhile, revenues for the fourth-quarter reached $1.1 billion – up by five per cent on figures from the final quarter of 2008.

“We recorded our sixth consecutive year of double-digit EPS growth, TYSABRI became [our] third blockbuster product and we advanced two programmes into registrational trials,” said James Mullen, Biogen Idec’s president and chief executive officer.

In other Biogen Idec news, the organisation this week announced that it has recruited two experts in multiple sclerosis for the strengthening of its research and development in the area.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.